Stuart M Cain Selected Research

T-Type Calcium Channels (T-Type Calcium Channel)

1/2019	The T-type calcium channel blocker Z944 reduces conditioned fear in Genetic Absence Epilepsy Rats from Strasbourg and the non-epileptic control strain.
1/2019	The T-type calcium channel antagonist, Z944, alters social behavior in Genetic Absence Epilepsy Rats from Strasbourg.
1/2018	CaV 3.2 drives sustained burst-firing, which is critical for absence seizure propagation in reticular thalamic neurons.
10/2017	Sociability impairments in Genetic Absence Epilepsy Rats from Strasbourg: Reversal by the T-type calcium channel antagonist Z944.
12/2016	Heantos-4, a natural plant extract used in the treatment of drug addiction, modulates T-type calcium channels and thalamocortical burst-firing.
10/2016	The T-type calcium channel antagonist Z944 rescues impairments in crossmodal and visual recognition memory in Genetic Absence Epilepsy Rats from Strasbourg.
1/2016	The T-type calcium channel antagonist Z944 disrupts prepulse inhibition in both epileptic and non-epileptic rats.
5/2014	Low threshold T-type calcium channels as targets for novel epilepsy treatments.
7/2013	T-type calcium channels in burst-firing, network synchrony, and epilepsy.
2/2012	T-type calcium channel blockers that attenuate thalamic burst firing and suppress absence seizures.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stuart M Cain Research Topics

Disease

13	Absence Epilepsy (Childhood Absence Epilepsy) 06/2022 - 01/2009
9	Seizures (Absence Seizure) 01/2021 - 01/2009
6	Epilepsy (Aura) 01/2022 - 11/2010
1	Pain (Aches) 01/2020
1	Neurodevelopmental Disorders 11/2019
1	Migraine with Aura (Familial Hemiplegic Migraine) 01/2017
1	Migraine Disorders (Migraine) 01/2017
1	Substance-Related Disorders (Drug Abuse) 12/2016
1	Opioid-Related Disorders (Opiate Addiction) 12/2016
1	Memory Disorders (Memory Loss) 10/2016
1	Mental Disorders (Mental Disorder) 01/2016
1	Brain Diseases (Brain Disorder) 01/2016
1	Neuralgia (Stump Neuralgia) 01/2016
1	Breast Neoplasms (Breast Cancer) 10/2014
1	Hypertension (High Blood Pressure) 05/2014
1	Sleep Initiation and Maintenance Disorders (Insomnia) 05/2014
1	Pathologic Processes 05/2014
1	Cancer Pain 05/2014
1	Cardiomegaly (Heart Hypertrophy) 09/2010
1	Bipolar Disorder (Manic Depressive Psychosis) 08/2009
1	Generalized Epilepsy 01/2009

Drug/Important Bio-Agent (IBA)

13	T-Type Calcium Channels (T-Type Calcium Channel)IBA 01/2019 - 01/2009
7	Z944IBA 01/2019 - 02/2012
5	CalciumIBA 01/2017 - 01/2009
3	Calcium Channels (Calcium Channel)IBA 01/2020 - 11/2010
3	Anticonvulsants (Antiepileptic Drugs)IBA 01/2020 - 08/2009
2	Cannabinoid Receptors (Cannabinoid Receptor)IBA 06/2022 - 01/2021
2	CannabinoidsIBA 01/2022 - 01/2021
2	Pregabalin (Lyrica)FDA Link 01/2020 - 01/2017
1	CannabidiolIBA 01/2021
1	EndocannabinoidsIBA 01/2021
1	Gabapentin (Neurontin)FDA LinkGeneric 01/2020
1	gamma-Aminobutyric Acid (GABA)IBA 01/2020
1	EnzymesIBA 11/2019
1	RNA (Ribonucleic Acid)IBA 01/2018
1	Lipid NanoparticlesIBA 01/2018
1	Q-Type Calcium Channels (Q-Type Calcium Channel)IBA 01/2017
1	voltage-dependent calcium channel (P-Q type)IBA 01/2017
1	CalnexinIBA 01/2017
1	Plant ExtractsIBA 12/2016
1	CatalaseIBA 10/2014
1	MibefradilIBA 10/2014
1	epigallocatechin gallate (epigallocatechin-3-gallate)IBA 10/2014
1	Ethosuximide (Zarontin)FDA LinkGeneric 02/2012
1	Valproic Acid (Depakote)FDA LinkGeneric 02/2012
1	IonsIBA 11/2010
1	Protein Isoforms (Isoforms)IBA 11/2010
1	Carbamazepine (Tegretol)FDA LinkGeneric 08/2009
1	Immunoglobulin E (IgE)IBA 01/2009
1	NucleotidesIBA 01/2009

Therapy/Procedure

3	Therapeutics 01/2020 - 01/2016
1	Oral Administration 12/2016